Answers are grounded in this paper and cite their sources.
To evaluate the performance of MRI-derived radiomic risk score (RRS) and PD-L1 expression to predict overall survival (OS) and progression-free survival (PFS) of patients with recurrent head and neck squamous cell carcinoma receiving nivolumab therapy.
No takes yet. Share an insight, caveat, or question.
Sim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: